Tenderwize
Retour à la recherche

Open House Contract for Peginterferon beta 1a

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2028 · 704 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 20 - Peginterferon beta 1a

56/100

Score d'opportunité

Needs reviewHigh complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

56 / 100

Complexité

68 / 100

Facteurs de risque

Offers/contracts cannot be submitted through the e-procurement portal; the notice says this is technically not possible...

Only pharmaceutical undertakings meeting AMG and seat/authorisation conditions may contract.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jul 2028
  • Conclude non-exclusive discount agreements for Peginterferon beta 1a under § 130a Abs. 8 SGB V.
  • Provide pharmaceutical products for nationwide performance in Germany.
Afficher le résumé complet

This is a German Open House supply arrangement by Techniker Krankenkasse for the active substance Peginterferon beta 1a (CPV 33600000 Pharmaceutical products). It is not an exclusive award procedure: all pharmaceutical undertakings meeting the stated conditions may enter into the contract on uniform terms. The contract term is up to 24 months from 01.08.2026 and ends no later than 31.07.2028, with earlier automatic termination if patent/market exclusivity ends. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post. No contract value is stated.

Risques

Offers/contracts cannot be submitted through the e-procurement portal; the notice says this is technically not possible...

Only pharmaceutical undertakings meeting AMG and seat/authorisation conditions may contract.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of § 4 Abs. 18 AMG for the offered medicine(s).
  • Applicant must have its registered seat in the scope of the AMG, another EU Member State, or another EEA state.
  • Applicant must have a valid authorisation for the contract medicine or otherwise be entitled to market it in its own name.

Critères d'attribution

Lot 1

No substantive award criteria stated; form-only criterion in an Open House procedure.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Contract for Peginterferon beta 1a

Open House supply arrangement for Peginterferon beta 1a. The notice indicates nationwide performance in Germany. Contract terms are uniform and non-exclusive; no individual negotiations are conducted. The lot information is taken from structured data and XML notice.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jul 2026 - Jul 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No substantive award criteria stated; form-only criterion in an Open House procedure.

Date limite

Deadline Jul 30, 2028

Détails de la procédure

Date de publication
31 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
372206-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3